Fig. 5

Reduction of tumour cell proliferation, apoptosis induction and modulation of lipid metabolism by Bio-nFeR. a Confocal images of KI-67 immunofluorescence of tissue slides from control or Bio-nFeR treated lung cancer, melanoma and colorectal (CRC) cancer xenografts. b TUNEL assay, showing the levels of apoptosis induction at both doses used (upper panels correspond to 100 mg/kg-treated lung cancer xenografts and lower panels to 150 mg/kg-treated colon cancer xenografts). c Individual dihydroceramides composition of lung (LC), melanoma (MEL) and colorectal (CRC) tumours treated with Bio-nFeR at single 100–150 mg/Kg administration were identified by acyl chain, normalized to control and plotted as fold change. d The amount of sphinganine in the same samples as in A and B, normalized to control and plotted as fold change. e Immunoblot analysis of CSC antigens ALDH1, CD44V6 and Bmi-1 in the indicated control (−) or Bio-nFeR treated (+) xenografts. β-actin blot was used for equal loading control